Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
NCT05515978
This study is recruiting at 4 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation of metformin for these off-label indications is variable, often at the level of the provider. Multiple retrospective investigations have also shown a clinical benefit in men with prostate cancer who are incidentally treated with metformin.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- University of Colorado, Denver
- Last updated on ClinicalTrials.gov
- June 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 4
- Colorado Research Center · Aurora, CO
- UCHealth-Southern Colorado · Colorado Springs, CO
- UCHealth-Metro Denver · Denver, CO
- UCHealth-Northern Colorado · Fort Collins, CO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.